Humulin R Patent Expiration

Humulin R is a drug owned by Eli Lilly And Co. It is protected by 1 US drug patent filed in 2016 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 09, 2024. Details of Humulin R's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7291132 Medication dispensing apparatus with triple screw threads for mechanical advantage
Aug, 2024

(2 months ago)

Expired


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Humulin R's patents.

Given below is the list of recent legal activities going on the following patents of Humulin R.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 12th Year, Large Entity 11 Apr, 2019 US7291132
Post Issue Communication - Certificate of Correction 09 Sep, 2008 US7291132
Post Issue Communication - Certificate of Correction 23 Jun, 2008 US7291132
Patent Issue Date Used in PTA Calculation 06 Nov, 2007 US7291132
Recordation of Patent Grant Mailed 06 Nov, 2007 US7291132
Email Notification 19 Oct, 2007 US7291132
Issue Notification Mailed 17 Oct, 2007 US7291132
Dispatch to FDC 04 Oct, 2007 US7291132
Application Is Considered Ready for Issue 01 Oct, 2007 US7291132
Issue Fee Payment Received 28 Sep, 2007 US7291132


FDA has granted several exclusivities to Humulin R. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Humulin R, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Humulin R.

Exclusivity Information

Humulin R holds 1 exclusivities. All of its exclusivities have expired in 2014. Details of Humulin R's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
NR(NR) Mar 25, 2014

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Humulin R is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Humulin R's family patents as well as insights into ongoing legal events on those patents.

Humulin R's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Humulin R's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Aug 09, 2024 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Humulin R Generics:

There are no approved generic versions for Humulin R as of now.

Alternative Brands for Humulin R

Humulin R which is used for managing symptoms of depression and anxiety., has several other brand drugs using the same active ingredient (Insulin Recombinant Human). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name
Lilly
Humulin 70/30
Humulin 70/30 Pen
Mannkind
Afrezza
Pfizer
Exubera






About Humulin R

Humulin R is a drug owned by Eli Lilly And Co. It is used for managing symptoms of depression and anxiety. Humulin R uses Insulin Recombinant Human as an active ingredient. Humulin R was launched by Lilly in 2015.

Approval Date:

Humulin R was approved by FDA for market use on 29 December, 2015.

Active Ingredient:

Humulin R uses Insulin Recombinant Human as the active ingredient. Check out other Drugs and Companies using Insulin Recombinant Human ingredient

Treatment:

Humulin R is used for managing symptoms of depression and anxiety.

Dosage:

Humulin R is available in injectable form for injection use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
500 UNITS/ML INJECTABLE Prescription INJECTION